查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1984097

影像CRO市場：依提供者類型、服務類型、診斷影像方式、臨床試驗階段、適應症及最終使用者分類－2026-2032年全球市場預測

Imaging CRO Market by Provider Types, Service Type, Imaging Modality, Phase of Clinical Trials, Indication, End-User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，成像 CRO 市場價值將達到 22.1 億美元，到 2026 年將成長到 23.5 億美元，到 2032 年將達到 33.5 億美元，複合年成長率為 6.09%。

主要市場統計數據
基準年 2025 22.1億美元
預計年份：2026年 23.5億美元
預測年份 2032 33.5億美元
複合年成長率 (%) 6.09%

建構現代影像臨床研究生態系統的框架，使營運能力與科學和監管要求一致，從而成功進行臨床試驗。

在目前診斷影像臨床研究領域，需要嚴格且獨立地整合營運能力、科學標準和法規遵從性，以支援生命科學和醫療設備公司的決策者。本執行摘要闡述了影響外包診斷影像服務的核心主題，並揭示了卓越營運、影像模式專業化和整合資料管理如何相互融合併影響臨床實驗設計和執行。以下分析提取了關鍵產業趨勢、細分市場洞察、區域特徵以及建議的策略應對措施，供高階主管用於最佳化供應商選擇、資源分配和試驗監管。

成像方式、數據整合和監管期望的進步如何融合，正在重新定義供應商的能力和臨床試驗運作。

画像診断技術、データ管理の実践、および規制当局の監視の進展により、画像診断臨床研究の分野は変革的な変化を経験しており、これらが相まってプロバイダーの役割とサービス提供モデルを再構築しています。ベンダーは、単一モダリティのサービス提供から、画像取得の監督、一元化された読影、および縦断的データの調和を組み合わせた統合プラットフォームへと移行しており、これにより複雑なエンドポイントや分散型試験要素をサポートしています。同時に、定量的画像バイオマーカーの採用拡大に伴い、標準化された撮影通訊協定、ベンダー横断的なキャリブレーション手法、およびベンダーに依存しない解析ツールチェーンへの投資が促進されています。

2025 年新關稅措施的營運影響：醫療影像服務採購本地化、成本分配策略和合約風險緩解。

2025年實施的新關稅措施的累積影響，進一步加劇了依賴跨境設備採購和跨國供應鏈的影像服務供應商的營運複雜性。關稅導致影像硬體、專用耗材和某些輔助技術的到貨成本增加，迫使服務提供者重新評估其籌資策略，最佳化庫存計劃，並重新審視其「卓越中心」模式和分散式服務交付的經濟效益。

一個多維分割框架，揭示了提供者類型、服務線、模式、臨床試驗階段、適應症和最終用戶如何影響影像研究中的決策。

了解市場如何按提供者類型、服務線、影像模式、臨床試驗階段、適應症和最終用戶進行細分，對於就供應商選擇和專案設計做出明智的決策至關重要。根據醫療機構的類型，全方位服務合約研究組織 (CRO)、專業影像核心實驗室和專注於影像的 CRO 之間的差異，決定了申辦方是獲得端到端的管理解決方案，還是僅獲得集中式影像解讀和影像管治方面的專業知識。根據服務類型，臨床影像服務、資料管理和整合、計劃管理和試驗支援以及法規和合規相關服務之間的差異，決定了影像服務在多大程度上融入更廣泛的試驗營運中，或作為獨立的技術服務外包。

美洲、歐洲、中東和非洲以及亞太地區的區域狀況和適應策略會影響基於影像的臨床試驗的實施和資料品質。

區域趨勢對基於影像的臨床研究服務的提供、合約簽訂和監管有顯著影響，並認知到這些差異對於全球專案規劃至關重要。美洲地區集中了許多大型學術研究中心和成熟的專業影像供應商網路，有利於開展需要嚴格影像標準和可擴展的集中式解讀服務的複雜、大規模臨床實驗。該地區的變革性因素包括日益重視互通性，以及與保險公司和監管機構就影像診斷衍生的替代終點進行積極討論，這些因素影響通訊協定設計和證據生成策略。

醫療影像服務供應商的策略、技術投資和夥伴關係模式如何影響競爭差異化和贊助商參與度？

少数の定評あるプロバイダーと、より広範な専門ラボ群が、イメージングサービスの競合情勢を総体として形成しており、各社の行動からは、スポンサーとの関与に影響を与えるいくつかの一貫したテーマが浮かび上がっています。主要企業は、拡張可能な画像管理プラットフォーム、檢驗済みの読影アルゴリズム、および拠点間での一貫したパフォーマンスを可能にする統合品管システムへの投資を通じて、差別化を図っています。一方、ニッチな画像診断コアラボは、モダリティに関する深い専門知識と治療領域の特化を武器に競争しており、複雑なエンドポイントに対応した、高度にカスタマイズされた通訊協定開発や読影者トレーニングを提供しています。

採取可操作的經營團隊措施，協調供應商能力、資料管治和合約方法，以確保強大的鏡像端點和營運彈性。

產業領導者應採取一系列切實可行的措施，以維持專案進度勢頭，管控營運風險，並從影像衍生終點中挖掘科學價值。首先，供應商選擇標準應與其在特定成像方式方面的專業知識以及標準化成像通訊協定的過往記錄相匹配，以確保不同機構和放射科醫生之間的一致性。其次，要求提供演算法和半自動解讀工具的透明檢驗文檔，並強制執行可審計的資料管理流程，以促進與監管機構的溝通。第三，優先選擇能夠證明具備在地採購和區域倉儲能力的供應商，並制定能夠應對供應鏈風險和關稅相關成本波動的籌資策略。

結合專家訪談、通訊協定標準和同行評審文獻的混合方法證據基礎，以檢驗操作知識和調查方法的嚴謹性。

本報告的研究途徑結合了與該領域專家的系統性一手研究、與行業相關人員的結構化定性訪談，以及對公開的監管指南和同行評審文獻的嚴謹二手分析，以確保評估的平衡性和檢驗。一手研究包括諮詢影像科學家、臨床實踐經理和監管實踐專家，以檢驗營運場景並識別臨床實驗實施中出現的新挑戰。這些訪談有助於建立貫穿本報告的分析框架，特別是模態選擇、放射科醫師檢驗和資料整合模式的框架。

將營運重點、監管準備和策略供應商選擇連結的全面觀點，可確保診斷影像有效協助實現臨床專案的目標。

本執行摘要概述了關鍵的營運、監管和商業考慮因素，旨在為依賴外包影像服務的團隊提供決策支援。摘要重點闡述了影像模式的專業化、資料整合能力以及不斷變化的監管預期如何改變供應商選擇標準和試驗計劃實踐。分析強調了就影像終點、標準化採集通訊協定以及針對人工和演算法輔助解讀的穩健檢驗流程達成早期跨職能共識的必要性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：按提供者類型分類的影像CRO市場

  • 全方位CRO服務
  • 影像核心實驗室
  • 專業圖像 CRO

第9章 成像 CRO 市場：依服務類型分類

  • 臨床影像服務
  • 資料管理與整合
  • 計劃管理和臨床實驗支持
  • 法規與合規

第10章 依診斷影像方式分類的影像CRO市場

  • 電腦斷層掃描（CT）
    • 多切面CT
    • 螺旋CT
  • 磁振造影（MRI）
    • 擴散張量造影
    • 功能性磁振造影
  • 正子斷層掃描（PET）
  • 超音波
    • 3D和4D超音波
    • 多普勒超音波

第11章 影像CRO市場：按階段分類的臨床試驗

  • 第一階段
  • 第二階段
  • 第三階段

第12章 影像CRO市場：依適應症分類

  • 循環系統
  • 感染疾病
  • 肌肉骨骼系統
  • 神經病學
  • 腫瘤學
  • 眼科

第13章 成像 CRO 市場：依最終用戶分類

  • 生技公司
  • 醫療設備製造商
  • 製藥公司
  • 研究和學術機構

第14章 成像CRO市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 影像CRO市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 影像CRO市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國影像CRO市場

第18章：中國影像CRO市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • ABX-CRO Advanced Pharmaceutical Services Forschungsgesellschaft mbH
  • Aragen Life Sciences Ltd.
  • Biospective Inc.
  • Biotrial
  • Bruker Corporation
  • Celentyx Ltd.
  • Charles River Laboratories, Inc.
  • CLARIO
  • EPS Corporation
  • Fortrea, Inc.
  • ICON PLC
  • Image Analysis Group
  • Intelerad Medical Systems Incorporated
  • IQVIA Inc.
  • IXICO plc
  • Median Technologies PLC
  • Medidata by Dassault Systemes SE
  • Medpace, Inc.
  • MERIT CRO, Inc.
  • Micron, Inc.
  • Mint Medical Inc.
  • MUSASHI IMAGE JOHO CO.,LTD.
  • Parexel International Corporation
  • Perceptive Informatics LLC
  • Radiant Sage LLC
  • Syneos Health
  • Visikol, Inc.
  • WCG Clinical, Inc.
Product Code: MRR-2E76C3E47FC3

The Imaging CRO Market was valued at USD 2.21 billion in 2025 and is projected to grow to USD 2.35 billion in 2026, with a CAGR of 6.09%, reaching USD 3.35 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.21 billion
Estimated Year [2026] USD 2.35 billion
Forecast Year [2032] USD 3.35 billion
CAGR (%) 6.09%

Framing the contemporary imaging clinical research ecosystem to align operational capabilities with scientific and regulatory demands for trial success

The imaging clinical research landscape demands a rigorous, independent synthesis of operational capabilities, scientific standards, and regulatory alignment to support decision-makers across life sciences and medical device organizations. This executive summary introduces the core themes that shape outsourced imaging services, highlighting how operational excellence, modality specialization, and integrated data management converge to influence trial design and execution. The following analysis distills critical industry movements, segmentation intelligence, regional nuances, and recommended strategic responses that executives can use to refine vendor selection, resource allocation, and trial oversight.

Throughout the report, emphasis is placed on practical implications rather than abstract trends, ensuring that insights can be applied to real-world program planning. The introduction frames key drivers such as rising sophistication in quantitative imaging endpoints, the need for interoperable data systems, and evolving regulatory expectations that together demand a more strategic approach to imaging CRO engagement. Consequently, readers will find a balanced view that connects technological advances with operational constraints, offering a foundation for subsequent sections that detail transformative shifts, tariff impacts, segmentation implications, regional considerations, and company-level behavior. By setting this context up front, the summary aims to accelerate comprehension and support rapid translation of intelligence into procurement, trial design, and partnership decisions.

How converging advances in imaging modalities, data integration, and regulatory expectations are redefining vendor capabilities and trial operations

The imaging clinical research field is experiencing transformative shifts driven by advances in imaging technologies, data practices, and regulatory scrutiny that together are reshaping provider roles and service delivery models. Vendors are moving beyond single-modality service delivery toward integrated platforms that combine image acquisition oversight, centralized reading, and longitudinal data harmonization to support complex endpoints and decentralized trial elements. At the same time, the growing adoption of quantitative imaging biomarkers is prompting investments in standardized acquisition protocols, cross-vendor calibration approaches, and vendor-agnostic analytic toolchains.

As a result of these changes, project teams must now emphasize tighter collaboration between clinical operations, imaging core labs, and biostatistics to ensure image-derived endpoints are robust and reproducible. Furthermore, the industry is seeing enhanced focus on cloud-based image management and secure federated learning approaches to preserve data privacy while enabling multi-site model development. In addition, regulatory dialogues are evolving to address validation of algorithmic reads and digital biomarkers, which increases the importance of transparent validation pathways and audit-ready data curation. These converging forces are encouraging providers to expand capabilities in data integration, quality assurance, and regulatory support, and they are influencing sponsors to prioritize vendors who can demonstrate systemic rigor and adaptive service models.

Operational implications of new 2025 tariff measures driving procurement localization, cost allocation strategies, and contractual risk mitigation in imaging services

The cumulative effect of new tariff measures implemented in 2025 has introduced additional operational complexity for imaging service providers that rely on cross-border equipment procurement and multinational supply chains. Tariff-driven increases in the landed cost of imaging hardware, specialized consumables, and certain ancillary technologies have compelled providers to re-evaluate procurement strategies, optimize inventory planning, and reconsider the economics of center-of-excellence models versus distributed service delivery.

Consequently, imaging providers have accelerated efforts to localize critical supply chains and to negotiate long-term supplier agreements that can stabilize pricing and service continuity. This shift has also intensified the rationale for leveraging remote image reading and centralized processing to mitigate the need for repeated on-site equipment deployments across trial sites. Moreover, sponsors and providers are increasingly assessing the total landed cost of trial execution when selecting imaging modalities or specifying scanner requirements in protocols, prioritizing solutions that reduce cross-border movements and associated customs complexity.

In parallel, the tariff environment has prompted more structured contract language around cost pass-through, risk allocation, and contingency planning to manage potential future trade policy fluctuations. As a transitional measure, some service providers are offering localized service bundles and regional warehouses to maintain service level commitments while absorbing some procurement cost volatility. Together, these adaptations illustrate how trade policy dynamics translate into pragmatic changes in vendor selection, operational planning, and contractual governance across imaging-focused clinical research programs.

A multidimensional segmentation framework revealing how provider types, service lines, modalities, trial phases, indications, and end users shape imaging research decisions

Understanding how the market segments across provider types, service lines, imaging modalities, clinical trial phases, indications, and end users is essential to making informed decisions about vendor selection and program design. Based on provider types, distinctions between full-service contract research organizations, specialized imaging core labs, and imaging-focused CROs determine whether a sponsor will receive an end-to-end managed solution or a targeted competency in centralized reads and imaging governance. Based on service type, differences among clinical imaging services, data management and integration, project management and trial support, and regulatory and compliance offerings shape the extent to which imaging is embedded within broader trial operations or contracted as a discrete technical service.

Further, based on imaging modality, variation across CT, MRI, PET, and ultrasound-and the sub-specializations such as multislice versus spiral CT, diffusion tensor and functional MRI, and 3D/4D versus Doppler ultrasound-creates important implications for site qualification, reader expertise, and acquisition protocol design. Based on phase of clinical trials, requirements in Phase I, Phase II, and Phase III studies differ in terms of endpoint validation, frequency of imaging assessments, and the degree of regulatory documentation required. Based on indication, the clinical focus on cardiology, infectious diseases, musculoskeletal, neurology, oncology, and ophthalmology drives modality selection and reader specialization to align with disease-specific imaging biomarkers. Finally, based on end-user, the needs of biotechnology firms, medical device companies, pharmaceutical companies, and research and academic institutions influence procurement behavior, desired contracting models, and expectations for scientific collaboration. When taken together, these segmentation lenses provide a multidimensional framework that supports targeted vendor evaluation, operational design choices, and resource allocation decisions.

Regional operational realities and adaptive strategies across the Americas, EMEA, and Asia-Pacific that influence imaging trial execution and data quality

Regional dynamics exert a material influence on how imaging clinical research services are delivered, contracted, and regulated, and acknowledging these differences is vital for global program planning. In the Americas, concentrations of leading academic centers and a well-established network of specialized imaging vendors facilitate complex, high-volume trials that demand rigorous imaging standards and scalable centralized reading operations. Transitional factors in the region include an emphasis on interoperability and an active payer and regulatory discourse around imaging-derived surrogate endpoints, which affects protocol design and evidence generation strategies.

Across Europe, the Middle East, and Africa, variability in reimbursement frameworks, regulatory harmonization efforts, and clinical infrastructure leads to a more heterogeneous service landscape. Sponsors operating in this region must plan for differentiated site qualification strategies and be prepared to manage varied scanner models, language requirements, and local data protection regimes. Meanwhile, Asia-Pacific presents a rapidly evolving environment in which investments in imaging hardware and academic clinical research capacity are accelerating, yet operational considerations such as regional standardization, investigator training, and logistics for imaging calibration remain focal points. In each region, transitional approaches-such as regional hubs for image processing, localized training programs, and adaptive contracting-help bridge capability gaps and support consistent data quality across multi-jurisdictional studies. This geographical perspective is essential for designing pragmatic, regionally sensitive imaging strategies that align with global program objectives.

How provider strategies, technology investments, and partnership models are shaping competitive differentiation and sponsor engagement in imaging services

A small number of well-established providers and a broader set of specialized labs collectively define the competitive landscape for imaging services, and company behaviors reveal several consistent themes that affect sponsor engagement. Leading providers are differentiating through investments in scalable image management platforms, validated reading algorithms, and integrated quality management systems that enable consistent cross-site performance. At the same time, niche imaging core labs are competing on depth of modality expertise and therapeutic area specialization, offering highly tailored protocol development and reader training that address complex endpoints.

These company-level strategies are accompanied by an increasing focus on partnerships and alliances that extend technical capabilities into areas such as AI-augmented reads, cloud-native data integration, and federated analytics for multi-site studies. Additionally, firms are broadening service portfolios to include regulatory consulting and evidence generation planning to reduce friction in sponsor workflows. Operationally, companies that emphasize transparent validation processes, robust audit trails, and client-accessible dashboards tend to gain preference among sponsors seeking both scientific rigor and operational transparency. Finally, competitive differentiation is also driven by the ability to deliver flexible contracting models and localized support, which helps enable multinational trials with consistent imaging standards and predictable timelines.

Practical actions for executives to align vendor capabilities, data governance, and contracting approaches to secure robust imaging endpoints and operational resilience

Industry leaders should adopt a set of pragmatic actions to maintain program momentum, manage operational risk, and capture scientific value from imaging-derived endpoints. First, align vendor selection criteria with specific modality expertise and evidence of standardized acquisition protocols to ensure consistency across sites and readers. Second, require transparent validation documentation for any algorithmic or semi-automated reading tools and insist on audit-ready data curation processes that facilitate regulatory interactions. Third, incorporate procurement strategies that account for supply chain risks and tariff-related cost variability by favoring vendors with demonstrable localized sourcing or regional warehousing capabilities.

Additionally, sponsors should embed cross-functional governance that brings imaging specialists, biostatisticians, and clinical operations into early protocol design to avoid rework and endpoint ambiguity. It is also advisable to prioritize providers that offer integrated data management and interoperability features to reduce manual reconciliation and accelerate data lock. Finally, consider contracting modalities that balance risk and flexibility, such as milestone-based payments tied to deliverables, while negotiating clear service-level agreements and contingency plans. Taken together, these actions will support more resilient trial execution, higher confidence in imaging endpoints, and smoother regulatory dialogues.

A mixed-methods evidence base integrating expert interviews, protocol standards, and peer-reviewed literature to validate operational insights and methodological rigor

The research approach underpinning this report combines systematic primary engagement with subject-matter experts, structured qualitative interviews with industry stakeholders, and rigorous secondary analysis of publicly available regulatory guidance and peer-reviewed literature to ensure a balanced and verifiable assessment. Primary engagements included consultations with imaging scientists, clinical operations leads, and regulatory affairs specialists to validate operational scenarios and identify emerging pain points in trial execution. These interviews informed the development of analytic frameworks used throughout the report, particularly with respect to modality selection, reader validation, and data integration patterns.

Secondary research encompassed a review of technical standards, imaging protocol guidelines, and recent publications on quantitative imaging biomarkers to contextualize operational best practices and regulatory expectations. Data synthesis emphasized triangulation across sources to enhance reliability and to surface consensus where possible. Throughout the methodology, careful attention was paid to documenting assumptions, maintaining traceability of insights to source inputs, and preserving confidentiality of primary contributors. Together, this mixed-methods approach yields a pragmatic, evidence-based foundation for the strategic guidance and recommendations offered in the report.

Summative perspective linking operational priorities, regulatory readiness, and strategic vendor choices to ensure imaging contributes reliably to clinical program objectives

This executive summary synthesizes key operational, regulatory, and commercial considerations that will inform decision-making for teams that rely on outsourced imaging services. It highlights how modality specialization, data integration capabilities, and evolving regulatory expectations are changing provider selection criteria and trial planning practices. The analysis reinforces the need for early, cross-functional alignment on imaging endpoints, standardized acquisition protocols, and robust validation pathways for both human reads and algorithm-assisted interpretations.

Moreover, the summary underscores the practical implications of supply chain and tariff pressures on procurement and contracting, suggesting that sponsors proactively integrate risk mitigation measures into their vendor strategies. Regional differences require tailored approaches to site qualification and data harmonization, while company-level behaviors point to the value of partnering with providers who combine domain expertise with transparent, scalable platforms. In closing, the conclusion urges sponsors to translate the insights into concrete changes in procurement, protocol development, and governance so that imaging contributes reliably to evidence generation and to the overall success of clinical programs.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Imaging CRO Market, by Provider Types

  • 8.1. Full-Service CROs
  • 8.2. Imaging Core Labs
  • 8.3. Specialized Imaging CROs

9. Imaging CRO Market, by Service Type

  • 9.1. Clinical Imaging Services
  • 9.2. Data Management & Integration
  • 9.3. Project Management & Trial Support
  • 9.4. Regulatory & Compliance

10. Imaging CRO Market, by Imaging Modality

  • 10.1. Computer Tomography (CT) Scan
    • 10.1.1. Multislice CT
    • 10.1.2. Spiral CT
  • 10.2. Magnetic Resonance Imaging (MRI)
    • 10.2.1. Diffusion Tensor Imaging
    • 10.2.2. Functional MRI
  • 10.3. Positron Emission Tomography (PET)
  • 10.4. Ultrasound
    • 10.4.1. 3D & 4D Ultrasound
    • 10.4.2. Doppler Ultrasound

11. Imaging CRO Market, by Phase of Clinical Trials

  • 11.1. Phase I
  • 11.2. Phase II
  • 11.3. Phase III

12. Imaging CRO Market, by Indication

  • 12.1. Cardiology
  • 12.2. Infectious Diseases
  • 12.3. Musculoskeletal
  • 12.4. Neurology
  • 12.5. Oncology
  • 12.6. Ophthalmology

13. Imaging CRO Market, by End-User

  • 13.1. Biotechnology Firms
  • 13.2. Medical Device Companies
  • 13.3. Pharmaceutical Companies
  • 13.4. Research & Academic Institutions

14. Imaging CRO Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Imaging CRO Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Imaging CRO Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Imaging CRO Market

18. China Imaging CRO Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. ABX-CRO Advanced Pharmaceutical Services Forschungsgesellschaft mbH
  • 19.6. Aragen Life Sciences Ltd.
  • 19.7. Biospective Inc.
  • 19.8. Biotrial
  • 19.9. Bruker Corporation
  • 19.10. Celentyx Ltd.
  • 19.11. Charles River Laboratories, Inc.
  • 19.12. CLARIO
  • 19.13. EPS Corporation
  • 19.14. Fortrea, Inc.
  • 19.15. ICON PLC
  • 19.16. Image Analysis Group
  • 19.17. Intelerad Medical Systems Incorporated
  • 19.18. IQVIA Inc.
  • 19.19. IXICO plc
  • 19.20. Median Technologies PLC
  • 19.21. Medidata by Dassault Systemes S.E.
  • 19.22. Medpace, Inc.
  • 19.23. MERIT CRO, Inc.
  • 19.24. Micron, Inc.
  • 19.25. Mint Medical Inc.
  • 19.26. MUSASHI IMAGE JOHO CO.,LTD.
  • 19.27. Parexel International Corporation
  • 19.28. Perceptive Informatics LLC
  • 19.29. Radiant Sage LLC
  • 19.30. Syneos Health
  • 19.31. Visikol, Inc.
  • 19.32. WCG Clinical, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL IMAGING CRO MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL IMAGING CRO MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL IMAGING CRO MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL IMAGING CRO MARKET SIZE, BY PROVIDER TYPES, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL IMAGING CRO MARKET SIZE, BY SERVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL IMAGING CRO MARKET SIZE, BY IMAGING MODALITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL IMAGING CRO MARKET SIZE, BY PHASE OF CLINICAL TRIALS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL IMAGING CRO MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL IMAGING CRO MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL IMAGING CRO MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL IMAGING CRO MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL IMAGING CRO MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES IMAGING CRO MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA IMAGING CRO MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL IMAGING CRO MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL IMAGING CRO MARKET SIZE, BY PROVIDER TYPES, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL IMAGING CRO MARKET SIZE, BY FULL-SERVICE CROS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL IMAGING CRO MARKET SIZE, BY FULL-SERVICE CROS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL IMAGING CRO MARKET SIZE, BY FULL-SERVICE CROS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL IMAGING CRO MARKET SIZE, BY IMAGING CORE LABS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL IMAGING CRO MARKET SIZE, BY IMAGING CORE LABS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL IMAGING CRO MARKET SIZE, BY IMAGING CORE LABS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL IMAGING CRO MARKET SIZE, BY SPECIALIZED IMAGING CROS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL IMAGING CRO MARKET SIZE, BY SPECIALIZED IMAGING CROS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL IMAGING CRO MARKET SIZE, BY SPECIALIZED IMAGING CROS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL IMAGING CRO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL IMAGING CRO MARKET SIZE, BY CLINICAL IMAGING SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL IMAGING CRO MARKET SIZE, BY CLINICAL IMAGING SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL IMAGING CRO MARKET SIZE, BY CLINICAL IMAGING SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL IMAGING CRO MARKET SIZE, BY DATA MANAGEMENT & INTEGRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL IMAGING CRO MARKET SIZE, BY DATA MANAGEMENT & INTEGRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL IMAGING CRO MARKET SIZE, BY DATA MANAGEMENT & INTEGRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL IMAGING CRO MARKET SIZE, BY PROJECT MANAGEMENT & TRIAL SUPPORT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL IMAGING CRO MARKET SIZE, BY PROJECT MANAGEMENT & TRIAL SUPPORT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL IMAGING CRO MARKET SIZE, BY PROJECT MANAGEMENT & TRIAL SUPPORT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL IMAGING CRO MARKET SIZE, BY REGULATORY & COMPLIANCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL IMAGING CRO MARKET SIZE, BY REGULATORY & COMPLIANCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL IMAGING CRO MARKET SIZE, BY REGULATORY & COMPLIANCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL IMAGING CRO MARKET SIZE, BY IMAGING MODALITY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL IMAGING CRO MARKET SIZE, BY COMPUTER TOMOGRAPHY (CT) SCAN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL IMAGING CRO MARKET SIZE, BY COMPUTER TOMOGRAPHY (CT) SCAN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL IMAGING CRO MARKET SIZE, BY COMPUTER TOMOGRAPHY (CT) SCAN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL IMAGING CRO MARKET SIZE, BY COMPUTER TOMOGRAPHY (CT) SCAN, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL IMAGING CRO MARKET SIZE, BY MULTISLICE CT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL IMAGING CRO MARKET SIZE, BY MULTISLICE CT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL IMAGING CRO MARKET SIZE, BY MULTISLICE CT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL IMAGING CRO MARKET SIZE, BY SPIRAL CT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL IMAGING CRO MARKET SIZE, BY SPIRAL CT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL IMAGING CRO MARKET SIZE, BY SPIRAL CT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL IMAGING CRO MARKET SIZE, BY MAGNETIC RESONANCE IMAGING (MRI), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL IMAGING CRO MARKET SIZE, BY MAGNETIC RESONANCE IMAGING (MRI), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL IMAGING CRO MARKET SIZE, BY MAGNETIC RESONANCE IMAGING (MRI), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL IMAGING CRO MARKET SIZE, BY MAGNETIC RESONANCE IMAGING (MRI), 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL IMAGING CRO MARKET SIZE, BY DIFFUSION TENSOR IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL IMAGING CRO MARKET SIZE, BY DIFFUSION TENSOR IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL IMAGING CRO MARKET SIZE, BY DIFFUSION TENSOR IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL IMAGING CRO MARKET SIZE, BY FUNCTIONAL MRI, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL IMAGING CRO MARKET SIZE, BY FUNCTIONAL MRI, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL IMAGING CRO MARKET SIZE, BY FUNCTIONAL MRI, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL IMAGING CRO MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY (PET), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL IMAGING CRO MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY (PET), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL IMAGING CRO MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY (PET), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL IMAGING CRO MARKET SIZE, BY ULTRASOUND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL IMAGING CRO MARKET SIZE, BY ULTRASOUND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL IMAGING CRO MARKET SIZE, BY ULTRASOUND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL IMAGING CRO MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL IMAGING CRO MARKET SIZE, BY 3D & 4D ULTRASOUND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL IMAGING CRO MARKET SIZE, BY 3D & 4D ULTRASOUND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL IMAGING CRO MARKET SIZE, BY 3D & 4D ULTRASOUND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL IMAGING CRO MARKET SIZE, BY DOPPLER ULTRASOUND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL IMAGING CRO MARKET SIZE, BY DOPPLER ULTRASOUND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL IMAGING CRO MARKET SIZE, BY DOPPLER ULTRASOUND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL IMAGING CRO MARKET SIZE, BY PHASE OF CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL IMAGING CRO MARKET SIZE, BY PHASE I, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL IMAGING CRO MARKET SIZE, BY PHASE I, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL IMAGING CRO MARKET SIZE, BY PHASE I, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL IMAGING CRO MARKET SIZE, BY PHASE II, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL IMAGING CRO MARKET SIZE, BY PHASE II, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL IMAGING CRO MARKET SIZE, BY PHASE II, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL IMAGING CRO MARKET SIZE, BY PHASE III, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL IMAGING CRO MARKET SIZE, BY PHASE III, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL IMAGING CRO MARKET SIZE, BY PHASE III, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL IMAGING CRO MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL IMAGING CRO MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL IMAGING CRO MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL IMAGING CRO MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL IMAGING CRO MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL IMAGING CRO MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL IMAGING CRO MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL IMAGING CRO MARKET SIZE, BY MUSCULOSKELETAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL IMAGING CRO MARKET SIZE, BY MUSCULOSKELETAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL IMAGING CRO MARKET SIZE, BY MUSCULOSKELETAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL IMAGING CRO MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL IMAGING CRO MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL IMAGING CRO MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL IMAGING CRO MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL IMAGING CRO MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL IMAGING CRO MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL IMAGING CRO MARKET SIZE, BY OPHTHALMOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL IMAGING CRO MARKET SIZE, BY OPHTHALMOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL IMAGING CRO MARKET SIZE, BY OPHTHALMOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL IMAGING CRO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL IMAGING CRO MARKET SIZE, BY BIOTECHNOLOGY FIRMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL IMAGING CRO MARKET SIZE, BY BIOTECHNOLOGY FIRMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL IMAGING CRO MARKET SIZE, BY BIOTECHNOLOGY FIRMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL IMAGING CRO MARKET SIZE, BY MEDICAL DEVICE COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL IMAGING CRO MARKET SIZE, BY MEDICAL DEVICE COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL IMAGING CRO MARKET SIZE, BY MEDICAL DEVICE COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL IMAGING CRO MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL IMAGING CRO MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL IMAGING CRO MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL IMAGING CRO MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL IMAGING CRO MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL IMAGING CRO MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL IMAGING CRO MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS IMAGING CRO MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS IMAGING CRO MARKET SIZE, BY PROVIDER TYPES, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS IMAGING CRO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS IMAGING CRO MARKET SIZE, BY IMAGING MODALITY, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS IMAGING CRO MARKET SIZE, BY COMPUTER TOMOGRAPHY (CT) SCAN, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS IMAGING CRO MARKET SIZE, BY MAGNETIC RESONANCE IMAGING (MRI), 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS IMAGING CRO MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS IMAGING CRO MARKET SIZE, BY PHASE OF CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS IMAGING CRO MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS IMAGING CRO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA IMAGING CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA IMAGING CRO MARKET SIZE, BY PROVIDER TYPES, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA IMAGING CRO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA IMAGING CRO MARKET SIZE, BY IMAGING MODALITY, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA IMAGING CRO MARKET SIZE, BY COMPUTER TOMOGRAPHY (CT) SCAN, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA IMAGING CRO MARKET SIZE, BY MAGNETIC RESONANCE IMAGING (MRI), 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA IMAGING CRO MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA IMAGING CRO MARKET SIZE, BY PHASE OF CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA IMAGING CRO MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA IMAGING CRO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA IMAGING CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA IMAGING CRO MARKET SIZE, BY PROVIDER TYPES, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA IMAGING CRO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA IMAGING CRO MARKET SIZE, BY IMAGING MODALITY, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA IMAGING CRO MARKET SIZE, BY COMPUTER TOMOGRAPHY (CT) SCAN, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA IMAGING CRO MARKET SIZE, BY MAGNETIC RESONANCE IMAGING (MRI), 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA IMAGING CRO MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA IMAGING CRO MARKET SIZE, BY PHASE OF CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA IMAGING CRO MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA IMAGING CRO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA IMAGING CRO MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA IMAGING CRO MARKET SIZE, BY PROVIDER TYPES, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA IMAGING CRO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA IMAGING CRO MARKET SIZE, BY IMAGING MODALITY, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA IMAGING CRO MARKET SIZE, BY COMPUTER TOMOGRAPHY (CT) SCAN, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA IMAGING CRO MARKET SIZE, BY MAGNETIC RESONANCE IMAGING (MRI), 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA IMAGING CRO MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA IMAGING CRO MARKET SIZE, BY PHASE OF CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA IMAGING CRO MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA IMAGING CRO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE IMAGING CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE IMAGING CRO MARKET SIZE, BY PROVIDER TYPES, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE IMAGING CRO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE IMAGING CRO MARKET SIZE, BY IMAGING MODALITY, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE IMAGING CRO MARKET SIZE, BY COMPUTER TOMOGRAPHY (CT) SCAN, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE IMAGING CRO MARKET SIZE, BY MAGNETIC RESONANCE IMAGING (MRI), 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE IMAGING CRO MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE IMAGING CRO MARKET SIZE, BY PHASE OF CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE IMAGING CRO MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE IMAGING CRO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST IMAGING CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST IMAGING CRO MARKET SIZE, BY PROVIDER TYPES, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST IMAGING CRO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST IMAGING CRO MARKET SIZE, BY IMAGING MODALITY, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST IMAGING CRO MARKET SIZE, BY COMPUTER TOMOGRAPHY (CT) SCAN, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST IMAGING CRO MARKET SIZE, BY MAGNETIC RESONANCE IMAGING (MRI), 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST IMAGING CRO MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST IMAGING CRO MARKET SIZE, BY PHASE OF CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST IMAGING CRO MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST IMAGING CRO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA IMAGING CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA IMAGING CRO MARKET SIZE, BY PROVIDER TYPES, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA IMAGING CRO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA IMAGING CRO MARKET SIZE, BY IMAGING MODALITY, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA IMAGING CRO MARKET SIZE, BY COMPUTER TOMOGRAPHY (CT) SCAN, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA IMAGING CRO MARKET SIZE, BY MAGNETIC RESONANCE IMAGING (MRI), 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA IMAGING CRO MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA IMAGING CRO MARKET SIZE, BY PHASE OF CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA IMAGING CRO MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA IMAGING CRO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC IMAGING CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC IMAGING CRO MARKET SIZE, BY PROVIDER TYPES, 2018-2032 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC IMAGING CRO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC IMAGING CRO MARKET SIZE, BY IMAGING MODALITY, 2018-2032 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC IMAGING CRO MARKET SIZE, BY COMPUTER TOMOGRAPHY (CT) SCAN, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC IMAGING CRO MARKET SIZE, BY MAGNETIC RESONANCE IMAGING (MRI), 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC IMAGING CRO MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC IMAGING CRO MARKET SIZE, BY PHASE OF CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC IMAGING CRO MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC IMAGING CRO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL IMAGING CRO MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN IMAGING CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. ASEAN IMAGING CRO MARKET SIZE, BY PROVIDER TYPES, 2018-2032 (USD MILLION)
  • TABLE 185. ASEAN IMAGING CRO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. ASEAN IMAGING CRO MARKET SIZE, BY IMAGING MODALITY, 2018-2032 (USD MILLION)
  • TABLE 187. ASEAN IMAGING CRO MARKET SIZE, BY COMPUTER TOMOGRAPHY (CT) SCAN, 2018-2032 (USD MILLION)
  • TABLE 188. ASEAN IMAGING CRO MARKET SIZE, BY MAGNETIC RESONANCE IMAGING (MRI), 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN IMAGING CRO MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 190. ASEAN IMAGING CRO MARKET SIZE, BY PHASE OF CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 191. ASEAN IMAGING CRO MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN IMAGING CRO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 193. GCC IMAGING CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 194. GCC IMAGING CRO MARKET SIZE, BY PROVIDER TYPES, 2018-2032 (USD MILLION)
  • TABLE 195. GCC IMAGING CRO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. GCC IMAGING CRO MARKET SIZE, BY IMAGING MODALITY, 2018-2032 (USD MILLION)
  • TABLE 197. GCC IMAGING CRO MARKET SIZE, BY COMPUTER TOMOGRAPHY (CT) SCAN, 2018-2032 (USD MILLION)
  • TABLE 198. GCC IMAGING CRO MARKET SIZE, BY MAGNETIC RESONANCE IMAGING (MRI), 2018-2032 (USD MILLION)
  • TABLE 199. GCC IMAGING CRO MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 200. GCC IMAGING CRO MARKET SIZE, BY PHASE OF CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 201. GCC IMAGING CRO MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 202. GCC IMAGING CRO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION IMAGING CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPEAN UNION IMAGING CRO MARKET SIZE, BY PROVIDER TYPES, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPEAN UNION IMAGING CRO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPEAN UNION IMAGING CRO MARKET SIZE, BY IMAGING MODALITY, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPEAN UNION IMAGING CRO MARKET SIZE, BY COMPUTER TOMOGRAPHY (CT) SCAN, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPEAN UNION IMAGING CRO MARKET SIZE, BY MAGNETIC RESONANCE IMAGING (MRI), 2018-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION IMAGING CRO MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPEAN UNION IMAGING CRO MARKET SIZE, BY PHASE OF CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION IMAGING CRO MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION IMAGING CRO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 213. BRICS IMAGING CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 214. BRICS IMAGING CRO MARKET SIZE, BY PROVIDER TYPES, 2018-2032 (USD MILLION)
  • TABLE 215. BRICS IMAGING CRO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. BRICS IMAGING CRO MARKET SIZE, BY IMAGING MODALITY, 2018-2032 (USD MILLION)
  • TABLE 217. BRICS IMAGING CRO MARKET SIZE, BY COMPUTER TOMOGRAPHY (CT) SCAN, 2018-2032 (USD MILLION)
  • TABLE 218. BRICS IMAGING CRO MARKET SIZE, BY MAGNETIC RESONANCE IMAGING (MRI), 2018-2032 (USD MILLION)
  • TABLE 219. BRICS IMAGING CRO MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 220. BRICS IMAGING CRO MARKET SIZE, BY PHASE OF CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 221. BRICS IMAGING CRO MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS IMAGING CRO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 223. G7 IMAGING CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 224. G7 IMAGING CRO MARKET SIZE, BY PROVIDER TYPES, 2018-2032 (USD MILLION)
  • TABLE 225. G7 IMAGING CRO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. G7 IMAGING CRO MARKET SIZE, BY IMAGING MODALITY, 2018-2032 (USD MILLION)
  • TABLE 227. G7 IMAGING CRO MARKET SIZE, BY COMPUTER TOMOGRAPHY (CT) SCAN, 2018-2032 (USD MILLION)
  • TABLE 228. G7 IMAGING CRO MARKET SIZE, BY MAGNETIC RESONANCE IMAGING (MRI), 2018-2032 (USD MILLION)
  • TABLE 229. G7 IMAGING CRO MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 230. G7 IMAGING CRO MARKET SIZE, BY PHASE OF CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 231. G7 IMAGING CRO MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 232. G7 IMAGING CRO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 233. NATO IMAGING CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 234. NATO IMAGING CRO MARKET SIZE, BY PROVIDER TYPES, 2018-2032 (USD MILLION)
  • TABLE 235. NATO IMAGING CRO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. NATO IMAGING CRO MARKET SIZE, BY IMAGING MODALITY, 2018-2032 (USD MILLION)
  • TABLE 237. NATO IMAGING CRO MARKET SIZE, BY COMPUTER TOMOGRAPHY (CT) SCAN, 2018-2032 (USD MILLION)
  • TABLE 238. NATO IMAGING CRO MARKET SIZE, BY MAGNETIC RESONANCE IMAGING (MRI), 2018-2032 (USD MILLION)
  • TABLE 239. NATO IMAGING CRO MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 240. NATO IMAGING CRO MARKET SIZE, BY PHASE OF CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 241. NATO IMAGING CRO MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 242. NATO IMAGING CRO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 243. GLOBAL IMAGING CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED STATES IMAGING CRO MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 245. UNITED STATES IMAGING CRO MARKET SIZE, BY PROVIDER TYPES, 2018-2032 (USD MILLION)
  • TABLE 246. UNITED STATES IMAGING CRO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. UNITED STATES IMAGING CRO MARKET SIZE, BY IMAGING MODALITY, 2018-2032 (USD MILLION)
  • TABLE 248. UNITED STATES IMAGING CRO MARKET SIZE, BY COMPUTER TOMOGRAPHY (CT) SCAN, 2018-2032 (USD MILLION)
  • TABLE 249. UNITED STATES IMAGING CRO MARKET SIZE, BY MAGNETIC RESONANCE IMAGING (MRI), 2018-2032 (USD MILLION)
  • TABLE 250. UNITED STATES IMAGING CRO MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED STATES IMAGING CRO MARKET SIZE, BY PHASE OF CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 252. UNITED STATES IMAGING CRO MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED STATES IMAGING CRO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 254. CHINA IMAGING CRO MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 255. CHINA IMAGING CRO MARKET SIZE, BY PROVIDER TYPES, 2018-2032 (USD MILLION)
  • TABLE 256. CHINA IMAGING CRO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 257. CHINA IMAGING CRO MARKET SIZE, BY IMAGING MODALITY, 2018-2032 (USD MILLION)
  • TABLE 258. CHINA IMAGING CRO MARKET SIZE, BY COMPUTER TOMOGRAPHY (CT) SCAN, 2018-2032 (USD MILLION)
  • TABLE 259. CHINA IMAGING CRO MARKET SIZE, BY MAGNETIC RESONANCE IMAGING (MRI), 2018-2032 (USD MILLION)
  • TABLE 260. CHINA IMAGING CRO MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 261. CHINA IMAGING CRO MARKET SIZE, BY PHASE OF CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 262. CHINA IMAGING CRO MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 263. CHINA IMAGING CRO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)